Abstract
Administration of GLP-1 analogues resistant to the action of DPP-IV or therapeutic inhibition of these enzymes, allowing increased levels of GLP-1 are completely new approaches treatment 2 diabetes mellitus type. Incretin therapy strategy holds great potential power to help patients with diabetes improve their unsatisfactory compensation, thereby reducing the risk of manifestation of vascular complications.
Low levels of circulating GLP-1 (and GIP) fasting rapidly increases after eating and are subsequently degraded by the effect of dipeptidyl peptidase IV (DPP-IV) to inactive forms. DPP-IV is widely present in the body enzymes which proteolytically degrade GLP-1 and GIP (and other mediators).
Preventing the inactivation effect of administration of DPP-IV inhibitors will lead to increased GLP-1 levels, which are at 2 diabetics Type reduced and consequently ensure the improvement of glucose homeostasis in these patients. DPP-IV inhibitors represent a major new class of PAD and their metabolic profile has a number of unique advantages for clinical treatment of patients with type 2 diabetes mellitus type.